OVERVIEW

Our Board consists of eight Directors, including four executive Directors, one non-executive Director, and three independent non-executive Directors. Our Directors are appointed for a term of three years and are eligible for re-election upon expiry of their term of office.

The Board is responsible for and has general power over the management and operation of our business. Its duties include formulating business strategies and investment plans, implementing resolutions passed at general meetings, and exercising other powers, functions, and responsibilities as stipulated in the Articles of Association. The Board oversees the development and review of the Company's policies and practices in areas such as corporate governance, risk management, internal control, and compliance with applicable legal and regulatory requirements.

DIRECTORS

The following table sets forth certain information about our Directors:

Name	Age	Position(s)	Date of joining our Group	Date of appointment as a Director	Roles and responsibilities	Relationship with other Directors and senior management
Executive Directors						
Dr. Wan Zhaokui (萬昭奎)	57	Chairman of the Board, executive Director and chief executive officer	February 14, 2018	November 10, 2017	Responsible for the overall strategic planning, business development and major operational decisions of the Company	None
Dr. Wang Jun (汪俊)	69	Executive Director and chief scientific officer	February 1, 2018	November 10, 2017	Responsible for presiding over the daily operation of the Company and leading the biological sciences division	None
Dr. Michael Lawrence Vazquez	69	Executive Director and executive vice president	March 1, 2018	November 19, 2020	Responsible for chemistry department operation and overseeing the Company's small-molecule research and development activities	None

Name	Age	Position(s)	Date of joining our Group	Date of appointment as a Director	Roles and responsibilities	Relationship with other Directors and senior management
Mr. Chen Yan (陳龑)	41	Executive Director, secretary of the Board, chief financing officer and the chief operating officer	February 1, 2018	November 10, 2017	Responsible for business development, budget oversight and presiding over the daily operation of the Company	None
Non-executive Directors						
Mr. Jin Qi (金祺)	38	Non-executive Director	May 11, 2018	May 11, 2018	Providing professional opinion and judgement to the Board	None
Independent non-executive Directors						
Dr. Yu Cheung Hoi (于常海)	71	Independent non-executive Director	November 21, 2025	November 21, 2025	Providing independent opinion and judgement to the Board	None
Dr. Shao Liming (邵黎明)	66	Independent non-executive Director	November 21, 2025	November 21, 2025	Providing independent opinion and judgement to the Board	None
Ms. Li Chuchu (李楚楚)	36	Independent non-executive Director	January 16, 2026	January 16, 2026	Providing independent opinion and judgement to the Board	None

Executive Directors

Dr. Wan Zhaokui (萬昭奎), aged 57, is the founder, the chairman of the Board, an executive Director and the chief executive officer of our Company.

Prior to founding our Group, Dr. Wan served as a senior principal scientist at Pfizer Inc. (a company listed on the NYSE, stock code: PFE) from October 2001 to July 2013. He then served as a director and the head of chemistry department at Johnson & Johnson (a company listed on the NYSE, stock code: JNJ) from September 2013 to February 2018, where he led the chemistry division and contributed to strategic R&D initiatives.

Dr. Wan obtained a bachelor's degree in chemistry from Fuyang Normal University (阜陽師範大學), formerly known as Fuyang Normal College (阜陽師範學院) in Anhui, the PRC in July 1991, a master's degree in materials science from University of Science & Technology of China (中國科學技術大學) in Anhui, the PRC in July 1994 and a doctorate degree in organic chemistry from Boston University in Massachusetts, the U.S. in October 1999. He completed his postdoctoral research at Harvard University in October 2001.

Dr. Wang Jun (汪俊), aged 69, is one of the co-founders, an executive Director and the chief scientific officer of our Company.

Prior to founding our Group, Dr. Wang worked as an assistant researcher at the Cancer Institute of the Chinese Academy of Medical Sciences (中國醫學科學院腫瘤醫院腫瘤研究所) from June 1983 to March 1987, and as a visiting scholar at Kyoto University from January 1986 to January 1987. He completed his postdoctoral research at the University of Texas Southwestern Medical Center from February 1994 to March 1996, and subsequently served as an assistant professor there from March 1996 to March 1999.

Dr. Wang served as a senior scientist at Molecumetics Ltd. from March 1999, the principal scientist and lead investigator at Merck & Co., Inc. from May 2000 to October 2008, the vice president at Sandia Pharmaceutical Technology (Shanghai) Co., Ltd. (桑迪亞醫藥科技(上海)有限責任公司) from 2008 to 2010, and the vice president at Shanghai Medicilon Inc. (上海美迪西生物醫藥股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 688202.SH) from July 2010 to January 2018.

Dr. Wang obtained a bachelor's degree in biophysics from Fudan University (復旦大學) in Shanghai, the PRC in January 1982, and a doctorate degree in physiology from Kobe University (神戶大學) in Kobe, Japan in March 1994. He completed his postdoctoral research from February 1994 to March 1996 at the University of Texas Southwestern Medical Center.

Dr. Michael Lawrence Vazquez, aged 69, is one of the co-founders, an executive Director and the executive vice president of our Company.

Prior to founding our Group, Dr. Vazquez held multiple roles at G.D. Searle & Company from January 1987 to December 1999, including senior research investigator and research scientist (level I and level Ⅱ). He then worked at Pharmacia Corporation from January 2000 to April 2003. Dr Vazquez held multiple roles at Pfizer Inc. (a company listed on the NYSE, stock code: PFE) from 2003 to 2017, with his last position being associate research fellow.

Dr. Vazquez obtained a bachelor's degree in chemistry from Northern Illinois University in Illinois, the U.S. in May 1980 and a doctorate degree in chemistry from Northwestern University in Illinois, the U.S. in August 1986. He completed two years of postdoctoral work at the Research Triangle Institute from 1985 to 1987.

Mr. Chen Yan (陳龑), aged 41, is one of the co-founders, an executive Director, the secretary of the Board, chief financing officer and chief operating officer.

Prior to founding our Group, he pursued a combined master's and doctoral programme in microbiology and biochemical pharmacy at China Pharmaceutical University (中國藥科大學) from 2006 to 2008. Although eligible to continue along an academic track, he elected to enter the industry to further strengthen his practical expertise and served as a sales manager at Jiangxi Tongda Pharmaceutical Co., Ltd. (江西通達醫藥有限公司) until October 2010, and later as a brand manager at Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. (國藥集團同濟堂(貴州)製藥有限公司) from July 2011 to August 2012.

He worked at Zhejiang Conba Pharmaceutical Co., Ltd. (浙江康恩貝製藥股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600572.SH) from March 2013 to July 2014, Wuhan QR Pharmaceuticals Limited (武漢啟瑞藥業有限公司) from July 2014 and Yantai Dongcheng Biochemicals Co., Ltd. (煙臺東誠藥業集團股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 002675.SZ) from December 2014 to July 2015. Later, he worked at ChangJiang Growth Capital Investment Co., Ltd. (長江成長資本有限公司) from January 2016 to August 2016. In March 2016, he founded Shanghai Suichi Pharmaceutical Technology Co., Ltd. (上海燧池醫藥科技有限公司).

Mr. Chen obtained a bachelor's degree in biotechnology from China Pharmaceutical University (中國藥科大學) in Jiangsu, the PRC in June 2006.

Non-executive Director

Mr. Jin Qi (金祺), aged 38, is a non-executive Director appointed by Kaitai Capital.

Mr. Jin has been working at Hangzhou Kaitai Investment Management Co., Ltd. (杭州凱泰資本管理有限公司) since June 2014 and is currently serving as a managing director.

Mr. Jin obtained a bachelor's degree in biotechnology from Zhejiang University (浙江大學) in Zhejiang, the PRC in July 2010 and a master's degree in management from Imperial College of Science, Technology and Medicine in London, the U.K. in November 2013.

Independent non-executive Directors

Dr. Yu Cheung Hoi (于常海), aged 71, is an independent non-executive Director.

Dr. Yu has over 35 years of professional dedication in the pharmaceutical and biotechnology fields. From July 1984 to September 1989, he served as a postdoctoral fellow and assistant researcher in the Departments of Anesthesiology and Neurology at the University of California, San Francisco. He then worked as a researcher and visiting associate professor at Stanford University School of Medicine from February 1994 to August 1996. From February 1994 to December 2001, he served as a lecturer and assistant professor in the Department of Biology at the Hong Kong University of Science and Technology (香港科技大學). Since December 2001, Dr. Yu has served as a professor and PhD supervisor at the Department of Neurobiology, Peking University Health Science Center (北京大學醫學部). He has also been serving as a deputy director of the Institute of Neuroscience at Peking University (北京大學神經科學研究所) from December 2006 to December 2018.

Dr. Yu has also served as the chairman of the Hong Kong Council for Testing and Certification (香港檢測和認證局) from January 2016 to December 2021 and a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange (香港聯交所生物科技諮詢小組) since April 2018.

In addition to his academic roles, Dr. Yu is the director of Hai Kang Life Corporation Limited (海康生命科技有限公司), chairman of the Hong Kong Biotechnology Organization (香港生物科技協會) since September 2009, and chairman of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance (粵港澳大灣區生物科技聯盟) since December 2017. He served as independent non-executive director at Sirnaomics Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 2257.HK) until October 2025 and currently holds the position of director at CR-CP Life Science Fund Management Limited since May 2021, Keen Vision Acquisition Corporation (a company listed on the NASDAQ, stock code: KVAC) since October 2021, YNBY International Ltd. (雲白國際有限公司) (a company listed on the Main Board of the Hong Kong Stock Exchange, stock code: 0030.HK) since November 2023 and Medtide Inc. (泰德醫藥(浙江)股份有限公司) (a company listed on the Main Board of the Hong Kong Stock Exchange, stock code: 3880.HK) since June 2025.

Dr. Yu obtained his bachelor of science in May 1976, master of science in October 1980 and doctor of philosophy in May 1984 from the University of Saskatchewan in Saskatoon, Canada.

Dr. Shao Liming (邵黎明), aged 66, is an independent non-executive Director.

Prior to joining our Group, Dr. Shao held various academic and leadership roles across top research institutions and pharmaceutical companies. He conducted his postdoctoral research at the Department of Chemistry and Chemical Biology at Harvard University in Massachusetts, the U.S. from 1993 to 1996 and then worked at the Department of Cellular and Molecular Biology at Harvard University.

He has held multiple roles at Sepracor Inc. progressing from scientist to senior director from 1998 to 2010, and then served as a senior director of the Department of Preclinical Research and Translational Medicine at Sunovion Pharmaceuticals Inc. from 2010 to 2012. Dr. Shao has served as a distinguished professor and PhD supervisor at the School of Pharmacy, Fudan University (復旦大學). Dr. Shao was previously a director of Xuzhou Shenlan Pharmaceutical Technology Co., Ltd. (徐州申蘭醫藥科技有限公司) and a director of Changzhou Shenlan Pharmaceutical Technology Co., Ltd. (常州申蘭醫藥科技有限公司)[1]. Since May 2026, Dr. Shao has served as an independent non-executive director at IMPACT Therapeutics, Inc (南京英派藥業股份有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 7630.HK).

Dr. Shao obtained a bachelor's degree in organic chemistry from Fudan University (復旦大學) in Shanghai, the PRC in July 1982. He later obtained his master's degree in industrial chemistry in March 1990 and doctoral degree in industrial chemistry in March 1990 from the University of Tokyo (日本東京大學) in Tokyo, Japan.

1 Xuzhou Shenlan Pharmaceutical Technology Co., Ltd. is a company established in PRC, whose business license was revoked in June 2020 due to no actual business operations. Changzhou Shenlan Pharmaceutical Technology Co., Ltd. is a company established in PRC, whose business license was revoked in June 2021 due to no actual business operations.

Ms. Li Chuchu (李楚楚), aged 36, is an independent non-executive Director.

Prior to joining our Group, Ms. Li accumulated extensive professional experience across international accounting firms, investment institutions and listed companies. She commenced her career at KPMG, where she provided audit services from 2012 to March 2015, and subsequently served in the advisory practice from April 2015 to December 2017. She then joined Verdant Capital Group Limited (環華資本集團有限公司) as an investment director from December 2017 to April 2020, where she was responsible for investment execution and portfolio management. From May 2020 to June 2023, Ms. Li served as the chief financial officer and executive director of Avantua Capital Management Limited (環裕資本管理有限公司), overseeing financial management, internal controls and corporate governance. Since September 2023, she has been serving as the chief financial officer, executive director and company secretary of Arta TechFin Corporation Limited (裕承科金有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 0279.HK). Since April 2026, Ms. Li has served as an independent non-executive director at Palasino Holdings Limited (百樂皇宮控股有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 2536.HK).

Ms. Li obtained a bachelor's degree in Professional Accountancy from The Chinese University of Hong Kong (香港中文大學) in August 2012 and is a Certified Public Accountant accredited by the Hong Kong Institute of Certified Public Accountants qualified in July 2017.

SENIOR MANAGEMENT

The following table provides information about members of our senior management:

Name	Age	Position(s)	Date of joining our Group	Date of appointment as senior management	Roles and responsibilities	Relationship with other Directors and senior management
Dr. Wan Zhaokui (萬昭奎)	57	Chairman of the Board, executive Director and chief executive officer	February 14, 2018	February 14, 2018	Responsible for the overall strategic planning, business development and major operational decisions of the Company	None
Dr. Wang Jun (汪俊)	69	Executive Director and chief scientific officer	February 1, 2018	February 1, 2018	Responsible for presiding over the daily operation of the Company and leading the biological sciences division	None
Dr. Michael Lawrence Vazquez	69	Executive Director and executive vice president	March 1, 2018	March 1, 2018	Responsible for chemistry department operation and overseeing the Company's small-molecule research and development activities	None
Mr. Chen Yan (陳龑)	41	Executive Director, secretary of the Board, chief financing officer and the chief operating officer	February 1, 2018	February 1, 2018	Responsible for business development, budget oversight and presiding over the daily operation of the Company	None

Dr. Wan Zhaokui (萬昭奎) is the chairman of the Board, an executive Director and the chief executive officer of our Company. See "– Directors – Executive Directors" in this section for his biographical details.

Dr. Wang Jun (汪俊) is an executive Director and the chief scientific officer of our Company. See "– Directors – Executive Directors" in this section for his biographical details.

Dr. Michael Lawrence Vazquez is an executive Director and executive vice president of our Company. See "– Directors – Executive Directors" in this section for his biographical details.

Mr. Chen Yan (陳龑) is an executive Director, secretary of the Board, chief financing officer and the chief operating officer of our Company. See "– Directors – Executive Directors" in this section for his biographical details.

INTERESTS OF DIRECTORS AND SENIOR MANAGEMENT

Saved as disclosed above, none of our Directors and senior management had been a director of any public company the securities of which were listed on any securities market in Hong Kong or overseas in the three years immediately preceding the date of this Document. Save as disclosed herein, and as further disclosed in Appendix VI to this Document titled "Statutory and General Information", to the best knowledge, information and belief of the Directors having made all reasonable inquiries, none of the Directors or the chief executive officer of our Company has any interest in the Shares which is required to be disclosed under Part XV of the Securities and Futures Ordinance. Save as disclosed herein, to the best knowledge, information and belief of the Directors having made all reasonable inquiries, there are no other matters with respect to the appointment of our Directors that need to be brought to the attention of the Shareholders, nor is there any information relating to our Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

As of the Latest Practicable Date, none of our Directors or senior management were related to other Directors or senior management of our Company.

JOINT COMPANY SECRETARIES

Mr. Chen Yan (陳龑) is a joint company secretary of our Company. See "– Directors – Executive Directors" in this section for his biographical details.

Ms. Leung Chi Ching (梁芷晴), with extensive experience in the corporate services field, was appointed as one of our joint company secretaries with effect from date of **[REDACTED]** Committee hearing to be convened in connection with the **[REDACTED]**. She is an assistant manager of company secretarial services of Vistra Corporate Services (HK) Limited. Ms. Leung obtained a Master of Science in Professional Accounting and Corporate Governance from City University in Hong Kong in 2021. She is an associate member of The Chartered Governance Institute in United Kingdom and The Hong Kong Chartered Governance Institute.

BOARD COMMITTEES

Our Board delegates certain responsibilities to various committees. In accordance with the relevant PRC laws and regulations and the Corporate Governance Code and the Listing Rules, our Company has formed three Board committees, namely the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee.

Audit Committee

We have established the Audit Committee in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Audit Committee consists of three Directors, namely Ms. Li Chuchu (李楚楚), Dr. Yu Cheung Hoi (于常海) and Dr. Shao Liming (邵黎明). Ms. Li Chuchu (李楚楚) currently serves as the chairperson of the Audit Committee. The primary duties of the Audit Committee include, but are not limited to, the following:

- monitoring and evaluating the work of external auditors, make recommendations on the appointment and replacement of external auditors;
- monitoring and evaluating the internal audit work, coordinating internal and external audits;
- reviewing the financial information and its disclosures of our Company;
- monitoring and evaluating the internal control work of our Company;

- coordinating the communication between the management, internal audit department and relevant departments and external auditors; and
- addressing other matters authorized by the Board.

Remuneration and Appraisal Committee

We have established a Remuneration and Appraisal Committee with written terms of reference in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Remuneration and Appraisal Committee consists of three Directors, namely Dr. Shao Liming (邵黎明), Dr. Wan Zhaokui (萬昭奎) and Dr. Yu Cheung Hoi (于常海). Dr. Shao Liming (邵黎明) serves as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee include, but are not limited to, the following:

- reviewing and approving remuneration proposals of members of our senior management in accordance with our Company's policies and objectives as approved by our Board from time to time;
- making recommendations to our Board concerning our Company's policy and structure for all Directors' and senior management remuneration and on the establishment of a formal and transparent procedure for developing remuneration policy, including, but not limited to, performance evaluation standards, procedures and evaluation systems;
- conducting the evaluation of the annual performance of all Directors and senior management;
- monitoring remuneration payable to all Directors and senior management;
- reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules; and
- addressing other matters authorized by the Board.

Nomination Committee

We have established a Nomination Committee with written terms of reference in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Nomination committee consists of two independent non-executive Directors, namely Dr. Shao Liming (邵黎明), Dr. Wan Zhaokui (萬昭奎) and Ms. Li Chuchu (李楚楚). Dr. Shao Liming (邵黎明) serves as the chairperson of the Nomination committee. The Nomination Committee is responsible for formulating the selection criteria and procedures for Directors and senior management, screening and reviewing candidates and their qualifications, and making recommendations to the Board on the following matters:

- nominating individuals for appointment as Directors or recommending the removal of existing Directors;
- appointing or removing members of senior management;
- reviewing and making recommendations to the Board on the composition and number of our Board with reference to our Company's business activities, the scale of assets and shareholding structure;
- reviewing the selection criteria and procedures applicable to Directors and senior management, and making recommendations to our Board on the formulation and refinement of such selection criteria and procedures;

- identifying individuals suitably qualified to become a member of our Board and senior management;
- reviewing the qualifications and suitability of candidates nominated for directorships and senior management, and making recommendations to our Board regarding the appointment of such candidates;
- addressing other matters authorized by our Board.

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

We offer our Director and senior management members, who are also the Company's employees, remuneration in the form of salaries, allowances and benefits in kind and performance related bonuses and pension scheme contributions. Our independent non-executive Directors receive fixed allowances with reference to the internal policies of our Company.

For the years ended December 31, 2024, 2025 and the three months ended March 31, 2026, the aggregate amount of remuneration paid or payable to our Directors amounted to approximately RMB10.5 million, RMB10.0 million and RMB2.21 million, respectively. Under the arrangement currently in force, we estimate the total remuneration before taxation, to be accrued to our Directors for the year ending December 31, 2026 to be approximately RMB9.18 million. The actual remuneration of Directors in 2026 may be different from the expected remuneration.

The total emoluments for the five highest paid individuals amounted to approximately RMB10.74 million, RMB10.28 million and RMB2.84 million, for the years ended December 31, 2024, 2025 and the three months ended March 31, 2026, respectively.

During the Track Record Period, no remuneration was paid to our Directors or any of the five highest paid individuals as an inducement to join, or upon joining, our Group. During the Track Record Period, no compensation was paid to, or receivable by, any of our Directors, former directors or the five highest paid individuals for the loss of office as director of any member of our Group or of any other office in connection with the management of the affairs of any member of our Group. None of our Directors waived any emoluments during the Track Record Period. Save as disclosed above, no other payments have been paid, or are payable, by our Company or any of our subsidiaries to our Directors or the five highest paid individuals during the Track Record Period.

Our Board will review and determine the remuneration and compensation packages of our Directors and senior management and will, following the **[REDACTED]**, receive recommendations from our Remuneration and Appraisal Committee which will take into account salaries paid by comparable companies, time commitment and responsibilities of our Directors and senior management and the performance of our Group.

CORPORATE GOVERNANCE

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, our Company complies or intends to comply with the corporate governance requirements under the Corporate Governance Code set out in Appendix C1 to the Listing Rules after the **[REDACTED]**.

Our Directors recognize the importance of incorporating elements of good corporate governance in the management structures and internal control procedures of our Group to achieve effective accountability. Our Company intends to comply with all code provisions in the Corporate Governance Code as set out in Appendix C1 to the Listing Rules after the **[REDACTED]** except for Code Provision C.2.1 of Part 2 of the Corporate Governance Code, which provides that the roles of chairman of the board and chief executive officer should be separate and should not be performed by the same individual.

The roles of chairman of the Board and chief executive officer of the Company are currently performed by Dr. Wan. In view of Dr. Wan's substantial contribution to our Group since our establishment and his extensive experience, we consider that having Dr. Wan acting as both our chairman and chief executive officer will provide strong and consistent leadership to our Group and facilitate the efficient execution of our business strategies. We consider it is appropriate and beneficial to our business development and prospects that Dr. Wan continues to act as both our chairman and chief executive officer after the **[REDACTED]**, and therefore currently do not propose to separate the functions of chairman and chief executive officer.

While this would constitute a deviation from Code Provision C.2.1 of Part 2 of the Corporate Governance Code, the Board believes that this arrangement will not impair the balance of power and authority between the Board and the management of our Company, given that: (i) there are sufficient checks and balances in the Board, as a decision to be made by our Board requires approval by at least a majority of our Directors, and our Board comprises three independent non-executive Directors, which is in compliance with the requirement under the Listing Rules; (ii) Dr. Wan and other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that he/she acts for the benefit and in the best interests of our Company and will make decisions for our Group accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which comprises experienced individuals who meet regularly to discuss issues affecting the operations of our Company. Moreover, the overall strategic and other key business, financial, and operational policies of our Group are made collectively after thorough discussion at both Board and senior management levels. The Board will continue to review the effectiveness of the corporate governance structure of our Group in order to assess whether separation of the roles of chairman of the Board and chief executive officer is necessary.

BOARD DIVERSITY POLICY

In order to enhance the effectiveness of our Board and to maintain the high standard of corporate governance, we have adopted a board diversity policy which sets out the objective and approach to achieve and maintain diversity of our Board. Pursuant to the board diversity policy, we seek to achieve Board diversity through the consideration of a number of factors when selecting the candidates to our Board, including, but not limited to, gender, skills, age, professional experience, knowledge, cultural background, education background, ethnicity and length of service. The ultimate decision of the appointment will be based on merit and the contribution which the selected candidates will bring to our Board.

Our board currently consists of one female Directors and seven male Directors. Our Directors have a balanced mix of knowledge and skills, including overall management and strategic development, finance and corporate governance in addition to industry experience relevant to our Group's operations and business. They obtained degrees in various majors including pharmacology, biology and finance. This diverse academic background allows the Board to approach challenges and opportunities from multiple angles, fostering innovative solutions and comprehensive strategies. We have three independent non-executive Directors with different industry backgrounds, representing more than one third of the members of our Board. Furthermore, our Board has a diverse age and gender representation. Taking into account our existing business model and specific needs as well as the different background of our Directors, the composition of our Board satisfies our board diversity policy.

Our Nomination Committee is responsible for reviewing the structure and diversity of the Board and selecting individuals to be nominated as Directors. After the **[REDACTED]**, our Nomination committee will monitor and evaluate the implementation of the board diversity policy from time to time to ensure its continued effectiveness, and, when necessary, make any revisions that may be required and recommend any such revisions to our Board for consideration and approval. The Nomination Committee will also include in annual reports a summary of the board diversity policy, including any measurable objectives set for implementing the board diversity policy and the progress on achieving these objectives.

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in November 2025 and (ii) understands the requirements under the Listing Rules that are applicable to him or her as a director of a **[REDACTED]** under the Listing Rules and the possible consequences of making a false declaration or giving false information to the Stock Exchange.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointment.

COMPLIANCE ADVISOR

We have appointed Red Sun Capital Limited as our compliance advisor (the "**Compliance Advisor**") pursuant to Rules 3A.19 of the Listing Rules. The Compliance Advisor will provide us with guidance and advice as to compliance with the Listing Rules and other applicable laws, rules, codes and guidelines. Pursuant to Rule 3A.23 of the Listing Rules, the Compliance Advisor will advise our Company in certain circumstances, including:

(a) before the publication of any regulatory announcement, circular or financial report;

(b) where a transaction, which might be a notifiable or connected transaction is contemplated, including share issues and share repurchases;

(c) where we propose to use the **[REDACTED]** of the **[REDACTED]** in a manner different from that detailed in this Document or where our business activities, developments or results deviate from any forecast, estimate or other information in this Document; and

(d) where the Hong Kong Stock Exchange makes an inquiry to our Company regarding unusual movements in the price or **[REDACTED]** of its **[REDACTED]** or any other matters in accordance with Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, the Compliance Advisor will, on a timely basis, inform our Company of any amendment or supplement to the Listing Rules that are announced by the Hong Kong Stock Exchange. The Compliance Advisor will also inform our Company of any new or amended law, regulation or code in Hong Kong applicable to us, and advise us on the continuing requirements under the Listing Rules and applicable laws and regulations.

The term of the appointment of our Compliance Advisor will commence on the **[REDACTED]** and is expected to end on the date on which our Company complies with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the **[REDACTED]**.